0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Peptic Ulcer Disease, Cytoprotection, and Prostaglandins-Reply

STEVEN C. FISKE, MD
Arch Intern Med. 1990;150(3):695. doi:10.1001/archinte.1990.00390150161044.
Text Size: A A A
Published online

In Reply.—Drs Lauritsen and RaskMadsen's letter to the editor correctly presents disappointing results of recent trials of various prostaglandin analogues for the treatment of peptic ulcer disease. The editorial and case report in the October 1988 issue of the Archives1,2 did not propound prostaglandin analogues as the new therapeutic end-all for peptic ulcer disease. Rather, it discussed theoretical and physiologic mechanisms by which this multifactoral disease can be approached, and only suggested that "prostaglandin therapy has become a potentially promising new pharmacologic approach 'but' further clinical trials are anxiously awaited."1 Prostaglandin analogues do, however, appear to be of therapeutic value in nonsteroidal anti-inflammatory druginduced gastropathy, where histamine2 receptor blockers have been disappointing. Certainly, the potential for "abortion in a pill" and the frequently encountered diarrhea are major drawbacks to prostaglandin use without the appropriate indications.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();